Primo Biotech announced today a significant advancement in the development of PB-012, its proprietary radiotracer focusing on angiogenesis. The company has successfully completed the First Patient In (FPI) for the Phase I clinical trial at a medical center in Kaohsiung. This clinical trial aims to evaluate the diagnostic efficacy and safety of PB-012 in patients…

1Huang Ya-Ting, 1Chen Li-Yu, 2Chang Yen-Hsiang. 1 Primo Biotechnology Co., Ltd , Taipei, Taiwan. 2Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan. This study poster was presented at 2025 65th Annual Meeting of the Japanese Society of Nuclear Medicine (JSNM). Purpose: To evaluate the clinical benefit of Radium-223 (Ra-223) in delaying symptomatic skeletal…

1Chen Li-Yu, 1Huang Ya-Ting ,2Fan Yu-Ming. 1 Primo Biotechnology Co., Ltd , Taipei, Taiwan. 2Department of Nuclear Medicine, Cardinal Tien Hospital, New Taipei City, Taiwan.. This study poster was presented at 2025 65th Annual Meeting of the Japanese Society of Nuclear Medicine (JSNM). Purpose: To assess the cost-utility of 18F-fluorodeoxyglucose (FDG) imaging versus other diagnostic…

According to Taiwan’s National Health Insurance data, 9,858 new cases of prostate cancer and 1,897 related deaths were recorded in 2024, making it the third most common cancer among men and the fastest-growing malignancy in recent years. Prof. Yen-Chuan Ou, Superintendent of the Research and Innovation Center at Tung’s Taichung MetroHarbor Hospital, emphasized that the…